Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents

SARS-CoV-2 infections in children are generally asymptomatic or mild and rarely progress to severe disease and hospitalization. Why this is so remains unclear. Here we explore the potential for protection due to pre-existing cross-reactive seasonal coronavirus antibodies and compare the rate of anti...

Bibliografiset tiedot
Päätekijät:	Ratcliffe, H, Tiley, K, Longet, S, Tonry, C, Roarty, C, Watson, C, Amirthalingam, G, Vichos, I, Morey, E, Douglas, NL, Marinou, S, Plested, E, Aley, PK, Galiza, E, Faust, SN, Hughes, S, Murray, C, Roderick, MR, Shackley, F, Oddie, S, Lee, TWR, Turner, DPJ, Raman, M, Owens, S, Turner, PJ, Cockerill, H, Lopez Bernal, J, Ijaz, S, Poh, J, Shute, J, Linley, E, Borrow, R, Hoschler, K, Brown, KE, Carroll, MW, Klenerman, P, Dunachie, SJ, Ramsay, M, Voysey, M, Waterfield, T, Snape, MD
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Elsevier 2023

Samankaltaisia teoksia

Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Tekijä: Helen Ratcliffe, et al.
Julkaistu: (2023-12-01)

Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019–2021
Tekijä: Ratcliffe, H, et al.
Julkaistu: (2022)

The Role of Intestinal Epithelial Permeability in Multisystem Inflammatory Syndrome in Children: A Case–Control Study
Tekijä: Cathal Roarty, et al.
Julkaistu: (2024-08-01)

PANDEMIC HUMAN CORONAVIRUS – CHARACTERIZATION AND COMPARISON OF SELECTED PROPERTIES OF HCOV-SARS AND HCOV-MERS
Tekijä: Katarzyna W. Pancer
Julkaistu: (2018-06-01)

Development of Primer Panels for Whole-Genome Amplification and Sequencing of Human Seasonal Coronaviruses: hCoV-OC43, hCoV-HKU1, hCoV-229E, and hCoV-NL63
Tekijä: Tamila Musaeva, et al.
Julkaistu: (2024-12-01)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study [version 2; peer review: 2 approved]
Tekijä: Robert W. Aldridge, et al.
Julkaistu: (2020-12-01)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
Tekijä: Virginia Fuochi, et al.
Julkaistu: (2023-03-01)

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
Tekijä: Li-Jin Cui, et al.
Julkaistu: (2011-01-01)

Seroconversion to HCoV-NL63 in Rhesus Macaques
Tekijä: Lia van der Hoek, et al.
Julkaistu: (2009-10-01)

HCoV-NL63 and HCoV-HKU1 seroprevalence and its relationship with the clinical features of COVID-19 patients from Villavicencio, Colombia
Tekijä: Lida Carolina Lesmes-Rodríguez, et al.
Julkaistu: (2024-08-01)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
Tekijä: Sean A. Lynch, et al.
Julkaistu: (2021-08-01)

The transcriptional and translational landscape of HCoV-OC43 infection.
Tekijä: Stefan Bresson, et al.
Julkaistu: (2025-01-01)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
Tekijä: Yongkang Chen, et al.
Julkaistu: (2022-04-01)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
Tekijä: Jiangchao Xiang, et al.
Julkaistu: (2022-11-01)

55: DEVELOPMENT OF A NOVEL IN-VITRO HCOV-OC43 SCREENING METHOD
Tekijä: S. Haynes, et al.
Julkaistu: (2022-11-01)

The human coronavirus HCoV-229E S-protein structure and receptor binding
Tekijä: Zhijie Li, et al.
Julkaistu: (2019-10-01)

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
Tekijä: Martin Dugas, et al.
Julkaistu: (2021-04-01)

Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
Tekijä: Alvaro A. Ordonez, et al.
Julkaistu: (2022-03-01)

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
Tekijä: Yongmei Feng, et al.
Julkaistu: (2022-12-01)

Utilizing HCoV-OC43 to better understand the neurological impact of COVID-19
Tekijä: Catherine LaCourse
Julkaistu: (2024-12-01)

HCoV‐HKU1 and TMPRSS2 interaction: uncovering mechanisms of viral invasion
Tekijä: Zehan Pang, et al.
Julkaistu: (2025-01-01)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
Tekijä: Jang Hoon Kim, et al.
Julkaistu: (2023-12-01)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
Tekijä: Sophie Steiner, et al.
Julkaistu: (2020-12-01)

Co-circulation of Four Human Coronaviruses (HCoVs) in Queensland Children with Acute Respiratory Tract Illnesses in 2004
Tekijä: Theo P. Sloots, et al.
Julkaistu: (2012-04-01)

Corrigendum: Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
Tekijä: Yongmei Feng, et al.
Julkaistu: (2024-12-01)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
Tekijä: Jing Yang, et al.
Julkaistu: (2020-08-01)

Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry
Tekijä: Huan Sun, et al.
Julkaistu: (2020-01-01)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
Tekijä: Sébastien Pasquereau, et al.
Julkaistu: (2021-02-01)

Disinfection Effect of High-pressure Carbon Dioxide on Human Coronavirus (hCoV-229E)
Tekijä: Peng NING, et al.
Julkaistu: (2023-01-01)

A Mouse-Adapted Model of HCoV-OC43 and Its Usage to the Evaluation of Antiviral Drugs
Tekijä: Peifang Xie, et al.
Julkaistu: (2022-05-01)

Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
Tekijä: Nehemya Friedman, et al.
Julkaistu: (2018-09-01)

IL6-mediated HCoV-host interactome regulatory network and GO/Pathway enrichment analysis.
Tekijä: Gianfranco Politano, et al.
Julkaistu: (2020-09-01)

ESCRT Protein VPS4A Is Required for the Formation of Replication Centers and Replication of Human Coronavirus 229E (HCoV-229E)
Tekijä: Rinki Kumar, et al.
Julkaistu: (2024-08-01)

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Tekijä: Irene A. Abela, et al.
Julkaistu: (2024-02-01)

Comparison of Selected Characteristics of SARS-CoV-2, SARS-CoV, and HCoV-NL63
Tekijä: Darina Bačenková, et al.
Julkaistu: (2021-02-01)

Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN-γ ELISpot
Tekijä: Laura Thümmler, et al.
Julkaistu: (2021-08-01)

Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle
Tekijä: Xiaohuan Wang, et al.
Julkaistu: (2022-07-01)

Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes
Tekijä: Xiyong Song, et al.
Julkaistu: (2021-01-01)

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells.
Tekijä: Nehemya Friedman, et al.
Julkaistu: (2021-01-01)

Nasopharyngeal carriage of pneumococcus in children in England up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C
Tekijä: Tiley, KS, et al.
Julkaistu: (2022)